Johnson Lacey, Cameron Mathew, Waters Lauren, Padula Matthew P, Marks Denese C
Research and Development, Australian Red Cross Blood Service, Sydney, NSW, Australia.
School of Life Sciences and Proteomics Core Facility, Faculty of Science, University of Technology Sydney, Sydney, NSW, Australia.
Vox Sang. 2019 Jan;114(1):47-56. doi: 10.1111/vox.12730. Epub 2018 Nov 30.
Refrigeration (cold-storage) of pathogen inactivated (PI) platelet components may increase the shelf-life and safety profile of platelet components, compared to conventional room-temperature (RT) storage. Whilst there is substantial knowledge regarding the impact of these individual treatments on platelets, the combined effect has not been assessed.
Using a pool-and-split study design, paired buffy-coat derived platelets in 70% platelet additive solution (SSP+; MacoPharma) were left untreated or PI-treated using the THERAFLEX UV-Platelets System (UVC; MacoPharma). Units from each pair were split and stored at room temperature (20-24°C) or cold-stored (2-6°C) to yield RT, cold, RT-UVC and cold-UVC study groups (n = 8 in each group). In vitro quality and function was tested over 9 days.
Cold-storage of UVC-treated platelets reduced glycolytic metabolism (glucose consumption and lactate production) compared to RT-UVC units. Cold-UVC platelets demonstrated complete abrogation of HSR by day 5, increased externalisation of phosphatidylserine (annexin-V binding) and activation of the GPIIb/IIIa receptor (PAC-1 binding) above the levels observed with the individual treatments. Aggregation responses (ADP and collagen) were enhanced in the cold-UVC platelets compared to both RT groups, but this was primarily mediated by cold-storage. Haemostatic function, as measured using TEG, was similar between the groups.
Cold-storage of UVC-treated platelets reduced PI-induced acceleration of glycolytic metabolism. However, combining cold-storage and UVC-treatment resulted in additional phenotypic changes compared to each treatment individually. Further work is required to understand the impact of these changes in clinical efficacy.
与传统的室温储存相比，对病原体灭活（PI）的血小板成分进行冷藏（低温储存）可能会延长血小板成分的保质期并提高其安全性。虽然关于这些单独处理对血小板的影响已有大量知识，但尚未评估其联合效果。
采用混合分割研究设计，将70%血小板添加剂溶液（SSP+；Macopharma）中配对的来源于 Buffy 层的血小板不进行处理或使用 THERAFLEX UV - 血小板系统（UVC；Macopharma）进行PI处理。每对中的单位被分割并分别在室温（20 - 24°C）或冷藏（2 - 6°C）条件下储存，以形成室温、冷藏、室温 - UVC和冷藏 - UVC研究组（每组n = 8）。在9天内对体外质量和功能进行测试。
与室温 - UVC单位相比，冷藏UVC处理的血小板降低了糖酵解代谢（葡萄糖消耗和乳酸产生）。冷藏 - UVC血小板在第5天显示热休克反应完全消除，磷脂酰丝氨酸外化（膜联蛋白V结合）增加，并且糖蛋白IIb/IIIa受体激活（PAC - 1结合）高于单独处理时观察到的水平。与两个室温组相比，冷藏 - UVC血小板的聚集反应（ADP和胶原蛋白）增强，但这主要是由冷藏介导的。使用血栓弹力图测量的止血功能在各组之间相似。
冷藏UVC处理的血小板降低了PI诱导的糖酵解代谢加速。然而，与单独的每种处理相比，冷藏和UVC处理相结合导致了额外的表型变化。需要进一步开展工作以了解这些变化对临床疗效的影响。
